Subject(s)
Enalapril/administration & dosage , Enalaprilat/administration & dosage , Heart Failure/drug therapy , Heart Septal Defects, Ventricular/complications , Administration, Oral , Female , Heart Failure/etiology , Heart Failure/physiopathology , Hemodynamics/drug effects , Humans , Infant , Injections, Intravenous , MaleABSTRACT
The safety and efficacy of lisinopril in the treatment of mild to moderate essential hypertension was evaluated by Belgian general practitioners in patients whose hypertensive condition remained uncontrolled by previous treatment and/or in whom the prior drug regimen was not tolerated. In this 8-week study, 3060 eligible patients were initially treated with 20 mg lisinopril once daily; this dose was increased to 40 mg if diastolic blood pressure (DBP) was greater than 90 mm Hg after 4 weeks. Lisinopril monotherapy in the 1902 patients completing the trial resulted in marked reductions of systolic (SBP) and DBP from 172.5/102.4 mm Hg at baseline to 147.4/86.6 mm Hg by week 8. More than 90% of patients achieved a DBP less than 95 mm Hg. The decrease in blood pressure was similar in patients older and younger than 65 year of age. Only about 20% of patients required an increase in their daily intake of lisinopril to 40 mg. Treatment was well tolerated and the profile of adverse events was similar to the pattern found with other nonsulfydryl angiotensin converting enzyme inhibitors. Tolerance in the elderly was similar to that experience by hypertensives under 65 years of age. Thus, lisinopril at 20 or 40 mg once daily proved both well tolerated and effective in reducing blood pressure in patients with mild to moderate essential hypertension.
Subject(s)
Antihypertensive Agents/therapeutic use , Enalapril/analogs & derivatives , Hypertension/drug therapy , Aged , Antihypertensive Agents/adverse effects , Belgium , Blood Pressure/drug effects , Drug Tolerance , Enalapril/adverse effects , Enalapril/therapeutic use , Female , Humans , Lisinopril , Male , Middle Aged , Time FactorsABSTRACT
Belgian general practitioners studied the effect of enalapril over a period of 6 months on hypertension and quality of life in 4988 patients, whose hypertensive condition remained uncontrolled by previous treatments and/or in whom this previous drug regimen was not tolerated. Blood pressure was reduced from an average of 170/101 mm Hg at the onset of the trial to 145/85.5 mm Hg after 24 weeks. The treatment with enalapril was well tolerated and tolerance improved remarkably in the patients, whose previous treatment had caused intolerance. Quality of life, determined by means of the Nottingham Health Profile questionnaire, was favourably influenced in the patients participating in this study.
